

23 April 2025

Enlitic secures new migration & Ensignt agreements with estimated total contract value of approximately AU\$2.5m¹ in revenue

Highlights

- 20 new agreements executed, across migration technology contracts and Ensignt software license agreements.
 - Estimated total contract value of approximately AU\$2.5 million¹ in revenue
 - Expect 75% of revenue from these new agreements to be recognised in 2025, helping Enlitic propel towards operational cashflow break even by end of 2025
 - New wins across the business, through Enlitic's data migration technology and its Ensignt 2.0 data standardisation solution
 - Enlitic is now actively engaged with over 60% of the PACS OEM market
-

Enlitic, Inc. (ASX: ENL) ("the Company") is pleased to announce continued commercial momentum with twenty new agreements signed year-to-date in 2025. These agreements, comprising a mix of migration technology contracts and Ensignt Software License Agreements reflect strong demand for the Company's solutions and ongoing conversion of a robust open opportunity pipeline². Subject to successful validation testing, the contracts represent an estimated total contract value of approximately AU\$2.5 million in revenue for the Company, with 75% of this revenue to be recognised in 2025 with the balance to be recognised from the current period through to 2027. The new agreements contribute to Enlitic becoming operational cashflow break even by the end of 2025.

¹ US\$1.64M converted based on a USD:AUD exchange rate of 0.6429 as at 22 April 2025.

² Pipeline represents the total contracted minimum licence revenue to be charged over the term (generally 3 years of contracts entered with customers) of the contract plus ancillary revenue (as applicable). There is no guarantee that these opportunities will progress to End User License Agreements or generate any revenue for Enlitic.

Successful wins in data migration and standardisation

Expanding on the recent partnership announcement by GE HealthCare, Enlitic's migration business has also delivered new data migration agreements for leading healthcare providers such as University of California San Francisco, Regional West Health Services, and Guy's and St. Thomas NHS Foundation Trust, among others. These agreements further reinforce Enlitic's position as a trusted technology partner in the healthcare sector.

Enlitic has also entered into three new agreements for its Ensign solution with Alaska Radiology (Imaging Associates), National Cancer Institute Brigham & Women's Hospital/Harvard Medical School and RHCNZ Medical Imaging. All data migration and standardisation agreements are subject to standard validation testing.

While these new agreements may not be considered material individually in respect of their specific terms, conditions, or financial impact, Enlitic notes that collectively, they reflect continued progress in executing the Company's strategy and growing its presence across key markets.

Enlitic's CEO Michael Sistenich commented on the new contract wins, saying:

"These new agreements are a strong endorsement of Enlitic's strategic direction and solidify our role as a trusted partner for data standardisation and migration services. They reflect the positive momentum we are experiencing across our business and through our expanding partnerships, with active engagement now underway with over 60% of the PACS OEM market across our solution offerings.

"Conversions from our open opportunity pipeline¹ has seen a significant uptick since our acquisition of Laitek in late 2024, which added industry-leading data migration technology to the Enlitic portfolio. Today's announcement of 20 new agreements – secured in rapid succession, across both our migration and data standardisation offerings – underscores the impact of that strategic move.

"Enlitic remains focussed on enabling the healthcare industry's transition to innovative, reliable, and scalable imaging solutions, and we look forward to strengthening our partnerships across the global healthcare ecosystem."

– ENDS –

This announcement was authorised for release by the Board of Enlitic, Inc.

Enquiries

Enlitic Investor Relations

Australia:

invest_au@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.